Spike protein becomes the target protein for novel vaccines

On February 19, 2020 NIH scientists Wrapp et al published in Science the atomic structure of the SARS-CoV-2 spike protein, indicating their “findings will aid in the design of candidate vaccines and the development of treatments for COVID-19”. [1]

The study provided the first 3D map of the coronavirus spike, said to be “a breakthrough achievement that could speed the development of a SARS-CoV-2 vaccine” as it provides “valuable information to guide the development of medical counter-measures for 2019-nCoV”, now called SARS-CoV-2.

The virus binds to host cells through its trimeric spike glycoprotein, making this spike protein a key target for potential vaccines, therapies and diagnostics.

The researchers state “this protein binds at least 10 times more tightly” than SARS-CoV to their common host receptor – the human ACE2 receptor, and this affinity “may contribute to the apparent ease with which 2019-nCoV can spread from human to human.” [1]

Almost a month earlier Moderna had finalised their spike-protein targeted vaccine mRNA sequence